Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program
Clicks: 3
ID: 319169
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #194 of 214 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Optimal hepatitis C virus (HCV) screening is required to prevent transmission and progression to advanced liver disease and to meet global elimination targets. While administrative health data can highlight trends in testing and treatment, additional information is required to understand barriers in the care cascade. We conducted a real-world analysis documenting the care cascade and the effectiveness of HCV antibody (Ab) screening modalities across different community and clinical settings. Methods This was a cross-sectional study of individuals who completed HCV Ab testing at participating centers in Ontario, Canada, between May 2010 and June 2023. Results Among 61 605 individuals tested, the prevalence of HCV Ab was 13.6% and highest among individuals aged 35–44 years (23.2%) and individuals tested at addiction clinics (41.0%). Among those with an HCV Ab–positive result, 79.7% ever completed RNA testing of whom 57.3% were RNA positive. Among those with an RNA-positive result, 65.0% attended a follow-up appointment. Among those who attended their appointment, 94.0% initiated treatment (61.1% of the RNA-positive), 77.4% of those who started had documented treatment completion (47.3% of the RNA-positive), and 59.6% of those who completed treatment had documented sustained virologic response 12 weeks after treatment (28.2% of the RNA-positive). The Ab testing modality was closely related to test setting, and primary care was the most effective at linkage to care. Conclusions While there was some attrition from HCV Ab positivity to RNA testing, treatment initiation was higher compared with administrative data. These results highlight the benefits of multiple testing modalities and matching the optimal Ab testing modality to the setting, with strong pathways for linkage to care.
| Reference Key |
openalex_W7166821090
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Grishma Hirode, Camelia Capraru, Aaron Vanderhoff, Andrew Mendlowitz, Brett Wolfson-Stofko, Joel Karkada, David Smookler, Mediongo‐Abasi Usoro, Steven Friedman, Kathy Bates, Tony Mazzulli, Joshua V Juan, Hemant Shah, Bettina E. Hansen, Harry L A Janssen, Mia J. Biondi, Jordan J. Feld |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag218
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.